Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy
复制标题
DOI：
10.1038/nbt1154
复制
发表时间：
2005-11-01
影响因子：
46.9
通讯作者：
Figdor, CG
中科院分区：
文献类型：
--
作者：
de Vries, IJM;Lesterhuis, WJ;Figdor, CG
细胞疗法的成功将部分取决于将细胞准确递送到靶器官。特别是在树突状细胞治疗中，细胞向局部淋巴结的递送和随后的迁移对于有效刺激免疫系统是必不可少的。在这里，我们表明，在体内磁共振跟踪磁标记的细胞是可行的，在人类检测非常低的树突状细胞结合详细的解剖信息。自体树突状细胞标记的临床超顺磁性氧化铁制剂或在-111-oxine，并共同注射在黑色素瘤患者在超声引导下的结内。与放射成像相反，磁共振成像（MRI）允许评估树突状细胞递送的准确性以及结间和结内细胞迁移模式。使用氧化铁的MRI细胞跟踪在临床上是安全的，并且非常适合监测人类的细胞治疗。
The success of cellular therapies will depend in part on accurate delivery of cells to target organs. In dendritic cell therapy, in particular, delivery and subsequent migration of cells to regional lymph nodes is essential for effective stimulation of the immune system. We show here that in vivo magnetic resonance tracking of magnetically labeled cells is feasible in humans for detecting very low numbers of dendritic cells in conjunction with detailed anatomical information. Autologous dendritic cells were labeled with a clinical superparamagnetic iron oxide formulation or In-111-oxine and were co-injected intranodally in melanoma patients under ultrasound guidance. In contrast to scintigraphic imaging, magnetic resonance imaging (MRI) allowed assessment of the accuracy of dendritic cell delivery and of inter- and intra-nodal cell migration patterns. MRI cell tracking using iron oxides appears clinically safe and well suited to monitor cellular therapy in humans.